Evaluate the Safety and Therapeutic Effects of a Single Intravenous Infusion (IV) of Autologous CD34+ Cells Enriched With Allogenic Placenta-derived Mitochondria in Patients With a Diagnosis of Pearson Syndrome (PS)

Inclusion Criteria

• •1. Male or female participants aged from 1 to 18 years old.
• •2. Diagnosis of Pearson Syndrome (current or history) as verified by molecular identification of deletion in mtDNA of peripheral blood. Participants are diagnosed with PS Participant can be in either the PS manifestations of the disease or may have transitioned to Kearns Sayre Syndrome (KSS) manifestations but has a history of PS.
• •3. Participants have failure to thrive (height SDS smaller than -1)
• •4. Participants should have at least 12 months' history of body weight and height and calculated GFR (from creatinine) before treatment.
• •5. Body weight ≥ 10 kg.
• •6. Participants' living parent(s) and/or legal guardian(s) able to understand and provide voluntary written informed consent.
• •7. Participants' parents or legal guardian have a good understanding of the study and nature of the procedure and are expected to be able to comply with study visit schedules and caregiver assessments without difficulty.
• •8. Participants' parents or legal guardian provides written informed consent prior to study participation.
• •9. Participants are medically able to undergo the study interventions as determined by the Investigator.